ArticleFrontiers in cellular and infection microbiology2025
Investigating potential links between gut microbiome, clinical parameters, and mortality in long-living male patients receiving multi-drug therapy.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Multimorbidity and polypharmacy are common in long-living patients and have been linked to alterations in gut microbiota. However, the prognostic relevance of these microbiota changes remains unclear in this population. We hypothesized that clinical parameters and gut microbial profiles are associated with survival outcomes. This exploratory study aimed to investigate the relationships between intestinal microbiota, clinical variables, and 18-month mortality in long-living male patients undergoing multi-drug therapy. Methods: 33 long-living male adults (mean age 94 ± 4 years) were enrolled. Upon admission, clinical parameters and stool samples were collected. The composition of intestinal microbiome was examined using 16S rRNA gene sequencing technology. Subsequently, the patients were categorized into death and no-death groups based on their survival status after 18 months. Risk factors associated with 18-month mortality in patients were evaluated. Results: The 18-month mortality rate was 48.5%. In this exploratory analysis, higher CIRS-G scores and creatinine levels were independently associated with mortality (HR: 1.323 and 1.007, respectively). CIRS-G had high prognostic value (AUC = 0.967). IL-6 levels and renal/hepatic/pancreatic comorbidities were also elevated in the death group. Notably, Conclusions: CIRS-G scores and serum creatinine levels demonstrated potential predictability for prognostic value in forecasting mortality among long-living male patients. Moreover, a potential association between CIRS-G score and intestinal microbiome was observed. These results underscore the intricate impact of comorbidities and polypharmacy on intestinal microbiome composition and clinical consequences. Clinically, the CIRS-G score could serve as a valuable tool for identifying high-risk elderly patients who may benefit from closer monitoring and individualized interventions. However, the small sample size, monocentric design, and potential confounders limit generalizability. These findings support further validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.